Skip to main content
Premium Trial:

Request an Annual Quote

Mitsui Invests in Correlogic, Mulls Possible Japan-Based Joint Venture

NEW YORK, Feb. 10 (GenomeWeb News) - Tokyo-based Mitsui & Co. said today that it has made an undisclosed equity investment in clinical proteomics firm Correlogic Systems of Bethesda, Md.

The two companies have also signed a memorandum of understanding to "explore the possible creation of a Japan-based joint venture for deployment of Correlogic's diagnostic testing technology," Mitsui said in a statement.

Correlogic is the first US-based proteomics investment for the Bio-business Development Department of Mitsui's Performance Chemicals Unit, the company said.

Mitsui is "committed to developing molecular diagnostic business, especially for cancer, and is constantly searching for business partners to expand this core business interest," said Ryu Ogawa, COO of the Performance Chemicals Unit, in a statement.

Mitsui said it would validate Correlogic's technology with Japanese patients for a number of disease states, including cancers most prevalent in Japan.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.